SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77328.19
516.33 (-0.66%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Biocon Ltd.	Q V PT	61,684 Mid Cap	380.55 (-0.54%)	8380.53	2.3	2.44	-9.71	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Advanced Enzyme Technologies Ltd.	Q V PT	3,999 Small Cap	357.30 (-0.53%)	33.35	5.88	7.28	11.87	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Bajaj Healthcare Ltd.	Q V PT	1,134 Small Cap	336.90 (-0.88%)	21.87	2	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Gufic Biosciences Ltd.	Q V PT	3,008 Small Cap	300 (0.93%)	58.97	4.63	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Health X Platform Ltd.	Q V PT	947 Small Cap	297.75 (2.41%)	N/A	3.41	109.54	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Suraksha Diagnostic Ltd.	Q V PT	1,516 Small Cap	291.05 (1.43%)	44.89	6.29	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Fermenta Biotech Ltd.	Q V PT	850 Small Cap	288.70 (-4.07%)	12.3	2.14	7.46	0.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Bliss GVS Pharma Ltd.	Q V PT	2,849 Small Cap	269.35 (-0.94%)	37.9	2.56	8.59	-5.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Artemis Medicare Services Ltd.	Q V PT	4,201 Small Cap	265.35 (-0.28%)	43.38	3.6	10.15	32.48	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Wanbury Ltd.	Q V+ PT	887 Small Cap	254 (0.79%)	13.61	7.16	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	Park Medi World Ltd.	Q V PT	10,779 Small Cap	249.55 (1.40%)	1480.68	11.83	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Indoco Remedies Ltd.	Q V+ PT	2,106 Small Cap	228.20 (-9.17%)	N/A	2.17	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Tarsons Products Ltd.	Q V+ PT	1,211 Small Cap	227.65 (-0.31%)	36.91	1.81	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Suven Life Sciences Ltd.	Q V+ PT	5,911 Small Cap	224.15 (1.56%)	N/A	3.78	-14.30	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Viyash Scientific Ltd.	Q V PT	9,568 Small Cap	219 (-1.26%)	126.15	10.77	5.64	-18.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Jagsonpal Pharmaceuticals Ltd.	Q V+ PT	1,463 Small Cap	217.90 (2.13%)	33.25	5.19	11.13	39.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Laxmi Dental Ltd.	Q V PT	1,181 Small Cap	214.95 (-1.20%)	92.67	5.04	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Hikal Ltd.	Q V+ PT	2,600 Small Cap	210.90 (-1.08%)	N/A	2.21	4.29	-1.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Marksans Pharma Ltd.	Q V PT	8,968 Small Cap	197.90 (-2.58%)	37.37	5.92	22.06	32.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	Dishman Carbogen Amcis Ltd.	Q V+ PT	2,944 Small Cap	187.75 (-2.54%)	25.42	0.48	5.82	-33.01	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Piramal Pharma Ltd.	Q V PT	23,893 Small Cap	179.75 (-2.23%)	34.91	3	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	5,609 Small Cap	172.85 (3.53%)	N/A	-12.62	-1.35	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Shalby Ltd.	Q V PT	1,822 Small Cap	168.70 (0.75%)	24.37	1.52	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Fabtech Technologies Ltd.	Q V PT	725 Small Cap	163.05 (-1.48%)	30.33	1.89	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Kopran Ltd.	Q V PT	779 Small Cap	161.40 (-1.88%)	39.22	1.85	8.61	14.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	GPT Healthcare Ltd.	Q V PT	1,184 Small Cap	144.35 (1.55%)	28.77	4.43	13.96	24.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Gujarat Kidney And Super Speciality Ltd.	Q V+ PT	1,103 Small Cap	139.85 (6.84%)	710	N/A	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Themis Medicare Ltd.	Q V PT	902 Small Cap	97.96 (-0.86%)	N/A	3.04	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	IOL Chemicals And Pharmaceuticals Ltd.	Q V+ PT	2,847 Small Cap	96.98 (-0.92%)	24.79	1.62	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	KMC Speciality Hospitals (India) Ltd.	Q V PT	1,557 Small Cap	95.47 (6.85%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Metropolis Health.	550.30	8.83%
Shree Ganesh Remed.	530.60	8.65%
KMC Speciality Hosp	95.47	6.85%
Guj. Kidney & Super	139.85	6.84%
Nectar Lifesciences	14.39	5.89%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Indoco Remedies	228.20	-9.17%
Windlas Biotech	820.55	-4.24%
Panacea Biotec	388.15	-4.16%
Fermenta Biotech	288.70	-4.07%
Lupin	2,377.90	-3.33%

News about Top Pharma Companies in India

May, 2026

Biocon declines on reporting 63% fall in Q4 consolidated net profit

The total consolidated income of the company increased by 2.59% at Rs 4,569.10 crore for Q4FY26

May, 2026

Biocon reports 63% fall in Q4 consolidated net profit

The total consolidated income of the company increased by 2.59% at Rs 4,569.10 crore for Q4FY26

May, 2026

Biocon informs about earnings call

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Biocon has informed that it enclosed the presentation with respect to Q4 FY26 Earnings Call to be conducted on May 08, 2026. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Biocon informs about monitoring agency reports

Pursuant to Regulation 32(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 173A of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, Biocon has informed that it enclosed the Monitoring Agency Reports dated May 07, 2026 issued by India Ratings & Research, Monitoring Agency, in respect of utilisation of proceeds raised through Qualified Institutions Placements by the Company, for the quarter ended March 31, 2026. The Audit Committee and Board of Directors of the Company have reviewed and took note of the Monitoring Agency Reports at their respective meetings held on May 07, 2026. The above-mentioned information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Indoco Remedies - Quaterly Results

The sales for the March 2026 quarter moved up 29.34% to Rs. 4491.30 millions as compared to Rs. 3472.50 millions during the corresponding quarter last year.The Total Profit for the quarter ended March 2026 of Rs. 273.50 millions grew from Rs.-262.40 millionsOperating profit surged to 733.80 millions from the corresponding previous quarter of 99.60 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	4491.30	3472.50	29.34	16860.70	15181.90	11.06	16860.70	15181.90	11.06
Other Income	103.50	65.00	59.23	296.40	184.80	60.39	296.40	184.80	60.39
PBIDT	733.80	99.60	636.75	1867.90	1465.20	27.48	1867.90	1465.20	27.48
Interest	227.30	159.80	42.24	885.00	566.30	56.28	885.00	566.30	56.28
PBDT	543.30	-60.20	-1002.49	954.30	908.80	5.01	954.30	908.80	5.01
Depreciation	267.10	248.80	7.36	1069.00	982.50	8.80	1069.00	982.50	8.80
PBT	276.20	-309.00	-189.39	-114.70	-73.70	55.63	-114.70	-73.70	55.63
TAX	2.70	-46.60	-105.79	-58.10	13.60	-527.21	-58.10	13.60	-527.21
Deferred Tax	-26.50	-17.30	53.18	-87.30	13.60	-741.91	-87.30	13.60	-741.91
PAT	273.50	-262.40	-204.23	-56.60	-87.30	-35.17	-56.60	-87.30	-35.17
Equity	184.60	184.50	0.05	184.60	184.50	0.05	184.60	184.50	0.05
PBIDTM(%)	16.34	2.87	469.63	11.08	9.65	14.79	11.08	9.65	14.79

May, 2026

Bajaj Healthcare submits board meeting intimation

Bajaj Healthcare has informed that the meeting of the Board of Directors of the Company is scheduled on 08/05/2026, to consider and approve Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026; and recommend Final Dividend on Equity Shares if any, for the Financial Year 2025-26 subject to the approval of Shareholders of the Company at the ensuing Annual General Meeting of the Company.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Abbott India Ltd.	56,654 Crore
2	Neuland Laboratories Ltd.	22,701 Crore
3	Astrazeneca Pharma India Ltd.	21,223 Crore
4	Apollo Hospitals Enterprise Ltd.	1,16,392 Crore
5	Divis Laboratories Ltd.	1,78,100 Crore
6	Kovai Medical Center & Hospital Ltd.	6,209 Crore
7	Alkem Laboratories Ltd.	66,679 Crore
8	Procter & Gamble Health Ltd.	8,883 Crore
9	Dr Agarwals Eye Hospital Ltd.	2,465 Crore
10	Pfizer Ltd.	22,009 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,661	56,654	37.17	12.91	26.02	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	65.25	16.32	36.87	26.68
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	24.45
Lupin Ltd. (M)	Somewhat Good	2,378	1,08,721	20.39	4.84	11.79	20.83
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	110
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,364	66,722	67.00
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	40.02
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	37.62
Gland Pharma Ltd. (S)	Very Good	1,904	31,377	34.73
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	17.81
Mankind Pharma Ltd. (M)	Very Good	2,427	1,00,200	58.82	6.28	35.25	14.65
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	74.68	12.52	37.46	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	13.26
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	30.57
Cipla Ltd. (L)	Very Good	1,348	1,08,865	23.95	3.24	14.44	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,847	4,43,229	40.61	5.46	22.21	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	19.45

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Biocon declines on reporting 63% fall in Q4 consolidated net profit

Biocon reports 63% fall in Q4 consolidated net profit

Biocon informs about earnings call

Biocon informs about monitoring agency reports

Indoco Remedies - Quaterly Results

Bajaj Healthcare submits board meeting intimation

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.